SCHEMBL1157599

SCHEMBL1157599

CCCCSC[C@H](N)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 3/20 0.60
ARG1 P05089 1/20 0.56
ARG2 P78540 1/20 0.56
NOS1 P29475 2/20 0.54
NOS3 P29474 1/20 0.54
SLC1A2 P43004 3/20 0.47
SLC1A1 P43005 3/20 0.47
SLC1A3 P43003 2/20 0.47
GRIK1 P39086 4/20 0.46
GRIK2 Q13002 3/20 0.46
KIF11 P52732 2/20 0.45
BHMT Q93088 3/20 0.44
GMNN O75496 1/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
CYP2C9 P11712 1/20 0.42
BLM P54132 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14375190 1.00 NOS2 (0.60) NOS2ARG1ARG2NOS1NOS3
SCHEMBL1157602 1.00 NOS2 (0.60) NOS2ARG1ARG2NOS1NOS3
SCHEMBL2425458 0.94 NOS2 (0.58) NOS2ARG1ARG2NOS1NOS3
SCHEMBL2425454 0.94 NOS2 (0.58) NOS2ARG1ARG2NOS1NOS3
SCHEMBL9544550 0.92 NOS2 (0.57) NOS2ARG1ARG2NOS1NOS3
SCHEMBL11572921 0.92 NOS2 (0.57) NOS2ARG1ARG2NOS1NOS3
SCHEMBL3082543 0.92 NOS2 (0.57) NOS2ARG1ARG2NOS1NOS3
SCHEMBL3082545 0.92 NOS2 (0.57) NOS2ARG1ARG2NOS1NOS3
SCHEMBL20553470 0.92 NOS2 (0.57) NOS2ARG1ARG2NOS1NOS3
SCHEMBL10073278 0.92 NOS2 (0.57) NOS2ARG1ARG2NOS1NOS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2186512-A1 USE OF ALLYLCYSTEINE OR ITS ANALOGS AND PHARMACEUTICAL COMPOSITION THREROF Fudan University (CN) 2010-05-19 EP claimed
EP-0705603-B1 Use of non-toxic cysteine sulfoxide derivatives in the treatment of cancer HOLT JOHN ALFRED GORTON (AU) 2000-08-16 EP claimed
US-20250327074-A1 THE RARE CODON RECODING PLATFORM FOR NONCANONICAL AMINO ACIDS INCORPORATION IN MAMMALIAN CELLS SHAOXING INSTITUTE, ZHEJIANG UNIVERSITY (CN) 2025-10-23 US disclosed
US-10633630-B2 Acceleration of Mycobacterium growth ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) 2020-04-28 US disclosed
EP-3158053-B1 ACCELERATION OF MYCOBACTERIUM GROWTH ST GEORGES HOSPITAL MEDICAL SCHOOL (GB) 2019-03-13 EP disclosed
US-20170298099-A1 BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. 2017-10-19 US disclosed
US-9707282-B2 Small cationic antimicrobial peptides THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2017-07-18 US disclosed
US-20170121672-A1 ACCELERATION OF MYCOBACTERIUM GROWTH ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) 2017-05-04 US disclosed
EP-3158053-A1 ACCELERATION OF MYCOBACTERIUM GROWTH St. George's Hospital Medical School (GB) 2017-04-26 EP disclosed
US-20160108089-A1 BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES AILERON THERAPEUTICS, INC. 2016-04-21 US disclosed
WO-2015193688-A1 ACCELERATION OF MYCOBACTERIUM GROWTH ST GEORGE'S HOSPITAL MEDICAL SCHOOL (GB) 2015-12-23 WO disclosed
US-7361711-B2 Compositions for use in golf balls ACUSHNET COMPANY (US) 2008-04-22 US disclosed
US-7358309-B2 core or the layer includes a composition formed from a base polymer, a crosslink initiator, and at least one additive; additive has at least one carbon-oxygen-boron linkage, carbon in the linkage being a secondary or tertiary carbon; enhances coefficient of restitution and/or reduces compression of core ACUSHNET COMPANY (US) 2008-04-15 US disclosed
US-7358310-B2 Compositions for use in golf balls ACUSHNET COMPANY (US) 2008-04-15 US disclosed
US-7358308-B2 Compositions for use in golf balls ACUSHNET COMPANY (US) 2008-04-15 US disclosed
WO-2008022444-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2008-02-28 WO disclosed
US-20060281586-A1 Compositions for use in golf balls JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2006-12-14 US disclosed
US-20060281587-A1 Compositions for use in golf balls JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2006-12-14 US disclosed
US-20050245652-A1 Compositions for use in golf balls JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2005-11-03 US disclosed
US-20050245657-A1 Compositions for use in golf balls JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160108089-A1 BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES VIP, ANPEP, DNPEP NOS2 4009/4885ARG1 848/4885ARG2 791/4885
US-20170298099-A1 BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES VIP, ANPEP, DNPEP NOS2 4009/4885ARG1 848/4885ARG2 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.